John Knight, Lecturer in Cancer Biology, Division of Cancer Sciences at University of Manchester, shared on LinkedIn:
“Just two weeks left to apply for our fully funded PhD studentship looking at molecular déjà vu in AML.
The project is based in the Division of Cancer Sciences at the Manchester Cancer Research Centre. Co-supervised by Kiran Batta and Daniel Wiseman.
Acute myeloid leukaemia is characterised by mutations in genes whose products impact RNA and DNA biology.
Clinical management of the disease uses antimetabolite chemotherapies that work by being incorporated into RNA or DNA.
Join us to find out why AML is so dependent on regulation of it’s RNA and DNA.
You will use engineered isogenic cell models and cutting edge nucleic acid analyses to make new discoveries and advance your research career.
Apply through this link by the 23rd November: Molecular déjà vu: understanding RNA and DNA biology for precision therapy in AML.”
You can also read: Sorafenib Maintenance After Allo-SCT in FLT3-Mutated AML: Long-Term Survival Outcomes From a German Registry.
